The monthly e-newsletter of the nationally ranked University of Toledo College of Pharmacy and Pharmaceutical Sciences
Refill x
REFILL OCT 2014
2014 DISTINGUISHED ALUMNUS: Jerry Wisler, Class of 1979 PATIENT CARE AND BOARD CERTIFICATION Alumnus Brandon Craig, PharmD ‘07, discusses the benefits.
PG2 MISSION: UNSTOPPABLE Jing Meyer cheers students on toward academic and professional success.
PG3 THE MASTER OF PLANS Careful planning led to a meaningful career for BSPS alumnus, Kevin Krock ‘07.
PG4 LEADERSHIP LESSONS If graduate school is the next step, start planning now.
PG5
Gerald „Jerry‟ Wisler, BSP ‟79, is the recipient of the 2014 Distinguished Alumnus award from The University of Toledo Alumni Association. Nominated by his peers and selected by the college‟s Alumni Affiliate and Dean‟s Cabinet, he will be honored at the Homecoming Gala on October 24. The Distinguished Alumnus award is the highest honor and distinction the affiliate bestows on alumni, recognizing outstanding career achievements in pharmacy or healthcare. Wisler‟s unique educational background and career path have allowed him to contribute greatly to the lives of others. After earning his Bachelor of Science in Pharmacy, he completed a Master of Business Administration degree at The University of Toledo, with a major in finance. Wisler began his career as a practicing pharmacist but quickly moved into sales and promotion
roles in the pharmaceutical industry. His roles at Novartis and Merck included directing managed care and marketing strategy, in which he helped bring to market well known drugs like Pepcid® and Zocor®. Team building, strategic leadership and innovation are the hallmarks of Wisler‟s success in the pharmaceutical industry. The recipient of numerous awards for his entrepreneurialism and strategy, he independently established and led Aegerion Pharmaceuticals, Inc. and Omthera Pharmaceuticals, Inc. Through Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on latestage product de ve lopme nt and commercialization, Wisler led the completion of Phase 2 and Phase 3 trials, which culminated in the FDA approval of (Continued on page 4)